SMS Pharma.

Why is SMS Pharmaceuticals Ltd falling/rising?

As of 05-Aug, SMS Pharmaceuticals Ltd's stock price is rising slightly at 364.65, despite recent declines of 7.95% and 13.50% over the past week and month. The stock has strong year-to-date and annual performance but faces concerns regarding long-term fundamentals and declining investor participation.

As of 05-Aug, SMS Pharmaceuticals Ltd is experiencing a slight rise in its stock price, currently at 364.65, with a change of 1.15 (0.32%). This increase comes despite a recent trend of declining performance over the past week and month, where the stock has fallen by 7.95% and 13.50%, respectively. However, the stock has shown strong year-to-date performance, with a return of 17.57%, and a remarkable 64.55% increase over the past year, significantly outperforming the market benchmark.<BR><BR>The stock's current price rise can be attributed to its strong historical performance, particularly over the last year, where it has generated returns much higher than the broader market. Additionally, the stock is currently trading above its 200-day moving average, indicating some positive momentum. However, it is important to note that there has been a decline in investor participation, with delivery volume falling by 15.09% compared to the 5-day average, which could indicate a lack of sustained interest from investors.<BR><BR>Despite the recent price increase, there are underlying concerns regarding the company's long-term fundamentals, including a weak Return on Capital Employed (ROCE) of 9.88% and flat financial results in the most recent quarter. The company's net sales and profit after tax have both decreased compared to previous averages, which raises questions about its growth potential. Overall, while the stock is currently rising, it faces challenges that could impact its future performance.

Which are the latest news on SMS Pharma.?

Are SMS Pharmaceuticals Ltd latest results good or bad?

SMS Pharmaceuticals Ltd's latest results show mixed performance: while there was a year-on-year net profit growth of 2.05% and a net sales increase of 5.56%, quarterly results revealed significant declines with net profit down 36.07% and net sales down 13.02%, raising concerns about the company's stability. Overall, the results lean more negative due to these quarterly challenges.

The latest results for SMS Pharmaceuticals Ltd present a mixed picture. On one hand, the company achieved a year-on-year net profit growth of 2.05% and a net sales increase of 5.56%, which are positive indicators. However, these gains are overshadowed by significant quarter-on-quarter declines, with net profit dropping by 36.07% and net sales decreasing by 13.02%.<BR><BR>Despite the operational challenges reflected in these quarterly results, SMS Pharmaceuticals demonstrated improved operating margins, with the operating margin rising to 19.79% from 16.77% in the previous quarter. This suggests effective cost management, even as revenues contracted.<BR><BR>Overall, while there are some positive aspects, the sharp declines in both profit and sales on a quarterly basis raise concerns about the company's stability and growth trajectory. Therefore, the results can be seen as more negative than positive, indicating underlying volatility and challenges that need to be addressed.

Should I buy, sell or hold SMS Pharmaceuticals Ltd?

When is the next results date for SMS Pharmaceuticals Ltd?

The next results date for SMS Pharmaceuticals Ltd is August 1, 2026.

The next results date for SMS Pharmaceuticals Ltd is scheduled for August 1, 2026.

How big is SMS Pharma.?

As of 10th June, SMS Pharmaceuticals Ltd has a market capitalization of 3,562.00 Cr, with net sales of 886.88 Cr and a net profit of 101.98 Cr reported in the latest four quarters.

As of 10th June, SMS Pharmaceuticals Ltd has a market capitalization of 3,562.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, SMS Pharmaceuticals reported net sales of 886.88 Cr and a net profit of 101.98 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with shareholder's funds amounting to 639.64 Cr and total assets of 1,152.68 Cr.

Who are in the management team of SMS Pharma.?

The management team of SMS Pharma includes P Ramesh Babu (Chairman & Managing Director), P Sarath Kumar, Thummala Neelaveni, Shravan Kudaravalli, and Sarvepalli Srinivas (all Independent Directors), Vamsi Krishna Potluri (Executive Director), and Thirumalesh Tumma (Company Secretary & Compliance Officer). They oversee the company's operations and strategic direction.

The management team of SMS Pharma includes the following individuals:<BR><BR>1. **P Ramesh Babu** - Chairman & Managing Director<BR>2. **P Sarath Kumar** - Independent Director<BR>3. **Thummala Neelaveni** - Independent Director<BR>4. **Shravan Kudaravalli** - Independent Director<BR>5. **Sarvepalli Srinivas** - Independent Director<BR>6. **Vamsi Krishna Potluri** - Executive Director<BR>7. **Thirumalesh Tumma** - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Who are the peers of the SMS Pharma.?

SMS Pharma's peers include Advanced Enzyme, IOL Chemicals, RPG LifeScience, Gufic BioScience, Aarti Drugs, Panacea Biotec, Novartis India, Dishman Carbogen, Solara Active, and Zota Health Care. SMS Pharma has Below Average management risk and growth, with the highest 1-year return among peers at 49.20%.

Peers: The peers of SMS Pharma are Advanced Enzyme, IOL Chemicals, RPG LifeScience, Gufic BioScience, Aarti Drugs, Panacea Biotec, Novartis India, Dishman Carbogen, Solara Active, and Zota Health Care.<BR><BR>Quality Snapshot: Excellent management risk is observed at Advanced Enzyme, IOL Chemicals, RPG LifeScience, and Novartis India, while Average management risk is found at SMS Pharma, Gufic BioScience, Aarti Drugs, and the rest. Below Average management risk is noted for Panacea Biotec, Dishman Carbogen, Solara Active, and Zota Health Care. All peers exhibit Below Average growth except for Novartis India, which has Good growth, while SMS Pharma, Gufic BioScience, Aarti Drugs, and the rest show Below Average growth. Capital Structure ratings are Excellent for Advanced Enzyme, IOL Chemicals, and Novartis India, Good for Aarti Drugs, Average for SMS Pharma and Gufic BioScience, and Below Average for Panacea Biotec, Dishman Carbogen, Solara Active, and Zota Health Care.<BR><BR>Return Snapshot: The peer with the highest 1-year return is SMS Pharma at 49.20%, while the lowest is Dishman Carbogen at -37.99%. SMS Pharma's return is significantly higher than the lowest peer. Additionally, Dishman Carbogen and Aarti Drugs have negative six-month returns.

What does SMS Pharma. do?

SMS Pharmaceuticals Ltd manufactures Active Pharma Ingredients and intermediates in the pharmaceuticals sector. As of March 2026, it reported net sales of 238 Cr and a net profit of 33 Cr, with a market cap of INR 3,562 Cr.

Overview:<BR>SMS Pharmaceuticals Ltd is engaged in the manufacturing of Active Pharma Ingredients and their intermediates within the Pharmaceuticals & Biotechnology industry, categorized as a Small Cap company.<BR><BR>History:<BR>Incorporated in December 1987, SMS Pharmaceuticals Ltd has maintained its status in the pharmaceuticals sector. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 238 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 33 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 3,562 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 35.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.10%<BR>- Debt-Equity: 0.41<BR>- Return on Equity: 12.98%<BR>- Price to Book: 4.49<BR><BR>Contact Details:<BR>Address: 19 III Rd 71 Opp Bharatividya, Bhavan Public Sch Jubilee Hill Hyderabad Telangana : 500096<BR>Tel: 91-40-66288888<BR>Email: info@smspharma.com<BR>Website: http://www.smspharma.com

Is SMS Pharma. technically bullish or bearish?

As of November 26, 2025, the trend is bullish with strong indicators like MACD and Bollinger Bands supporting this, although caution is advised due to a mildly bearish KST and Dow Theory signals.

As of 26 November 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this position. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands also indicate a bullish trend on both time frames. The daily moving averages are bullish, reinforcing the positive momentum. However, the KST shows a mildly bearish signal on the monthly, and Dow Theory indicates a mildly bearish stance on the weekly, which suggests some caution. Overall, the strength of the bullish trend is supported by the strong performance in the last week, with a return of 13.99% compared to the Sensex's 0.50%.

Is SMS Pharma. overvalued or undervalued?

As of November 26, 2025, SMS Pharma is considered overvalued with a PE ratio of 35.81, an EV to EBIT ratio of 26.04, and a Price to Book Value of 4.14, all indicating a premium compared to peers, despite a strong year-to-date return of 34.50%.

As of 26 November 2025, the valuation grade for SMS Pharma has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios include a PE ratio of 35.81, an EV to EBIT ratio of 26.04, and a Price to Book Value of 4.14, all of which suggest a premium valuation compared to peers.<BR><BR>In comparison to its industry peers, SMS Pharma's PE ratio is higher than Sun Pharma's 37.53 and significantly above Cipla's more attractive 22.59. The PEG ratio of SMS Pharma stands at 1.26, which is on the higher side when compared to the industry average, further reinforcing the overvaluation stance. Notably, SMS Pharma has outperformed the Sensex with a year-to-date return of 34.50% compared to the Sensex's 9.56%, but this strong performance does not mitigate the concerns regarding its current valuation.

How has been the historical performance of SMS Pharma.?

SMS Pharma has shown consistent growth in net sales and profitability, with net sales increasing from 411.95 Cr in Mar'20 to 782.75 Cr in Mar'25, and profit after tax rising significantly to 67.40 Cr in Mar'25. Despite rising raw material costs and fluctuating cash flows, the company has improved operational efficiency and overall financial performance.

Answer:<BR>The historical performance of SMS Pharma shows a positive trend in net sales and profitability over the recent years, with significant fluctuations in certain metrics.<BR><BR>Breakdown:<BR>SMS Pharma's net sales have increased from 411.95 Cr in Mar'20 to 782.75 Cr in Mar'25, reflecting a consistent growth trajectory. Total operating income followed a similar pattern, rising from 464.91 Cr in Mar'19 to 782.75 Cr in Mar'25. However, the raw material costs also escalated, reaching 501.87 Cr in Mar'25, up from 259.50 Cr in Mar'20. Despite this increase in costs, the operating profit (PBDIT) rose to 145.22 Cr in Mar'25 from 93.49 Cr in Mar'19, indicating improved operational efficiency. Profit before tax saw a notable increase to 92.34 Cr in Mar'25, compared to 5.35 Cr in Mar'23, while profit after tax also improved significantly to 67.40 Cr in Mar'25 from just 3.88 Cr in Mar'23. The company's total assets grew from 607.91 Cr in Mar'20 to 1,152.68 Cr in Mar'25, alongside a rise in total liabilities from 607.91 Cr to 1,152.68 Cr over the same period. Cash flow from operating activities improved to 81.00 Cr in Mar'25, up from 22.00 Cr in Mar'23, although cash flow from investing activities showed a negative trend, reaching -123.00 Cr in Mar'25. Overall, SMS Pharma's financial performance indicates a robust growth in sales and profitability, despite rising costs and fluctuating cash flows.

Who are the top shareholders of the SMS Pharma.?

The top shareholders of SMS Pharma include the promoters, led by Ramesh Babu Potluri, and individual investors who hold 26.35% of the shares. Institutional investors, including mutual funds and foreign institutional investors, hold a combined total of 2.51%.

The top shareholders of SMS Pharma primarily include the promoters, who hold the majority of the shares. Notably, Ramesh Babu Potluri is the promoter with the highest holding, although his specific percentage is not detailed. <BR><BR>In terms of institutional investors, mutual funds hold a total of 2.43% through three different schemes, with Quant Mutual Fund - Quant Small Cap Fund being the highest public shareholder at 2.43%. Additionally, foreign institutional investors (FIIs) hold a minor stake of 0.08%. Individual investors collectively hold 26.35% of the company's shares. <BR><BR>Overall, the promoter group and individual investors are the key stakeholders in SMS Pharma.

Has SMS Pharma. declared dividend?

SMS Pharmaceuticals Ltd has declared a 40% dividend, amounting to ₹0.40 per share, with an ex-date of September 23, 2024. The company has shown strong long-term performance, with total returns of 477.41% over the past 5 years.

SMS Pharmaceuticals Ltd has declared a 40% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 40%<BR>- Amount per share: ₹0.40<BR>- Ex-date: 23 Sep 2024<BR><BR>Dividend Yield: 0.15%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -2.34%, with a dividend return of 0%, resulting in a total return of -2.34%.<BR><BR>Over the past year, the price return was 27.02%, the dividend return was 0.19%, leading to a total return of 27.21%.<BR><BR>In the last 2 years, the price return was 170.68%, with a dividend return of 0.76%, culminating in a total return of 171.44%.<BR><BR>For the 3-year period, the price return was 204.5%, the dividend return was 1.34%, resulting in a total return of 205.84%.<BR><BR>In the last 4 years, the price return was 55.42%, with a dividend return of 0.75%, leading to a total return of 56.17%.<BR><BR>Over the past 5 years, the price return was 475.4%, with a dividend return of 2.01%, resulting in a total return of 477.41%.<BR><BR>Overall, SMS Pharmaceuticals Ltd has declared a significant dividend, and the total returns over various periods indicate strong performance, particularly in the longer term, despite some fluctuations in the shorter periods.